Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 3,950 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,950 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $200.02, for a total value of $790,079.00. Following the transaction, the chief executive officer owned 156,607 shares in the company, valued at $31,324,532.14. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, February 3rd, Steven Leonard Chapman sold 4,725 shares of Natera stock. The shares were sold at an average price of $230.77, for a total value of $1,090,388.25.
• On Monday, February 2nd, Steven Leonard Chapman sold 85,299 shares of Natera stock. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total transaction of $881,499.84.

Natera Stock Up 3.4%

Natera stock opened at $207.04 on Wednesday. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The firm has a market cap of $29.34 billion, a PE ratio of -135.32 and a beta of 1.65. The company’s 50 day moving average is $225.25 and its two-hundred day moving average is $204.78.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.During the same quarter in the prior year, the company earned ($0.41) earnings per share. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Wells Fargo & Company lifted their price target on shares of Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Barclays raised their price objective on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Citigroup began coverage on shares of Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.47.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its position in Natera by 44.3% in the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Coatue Management LLC lifted its holdings in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. Norges Bank acquired a new stake in shares of Natera in the 2nd quarter valued at about $277,749,000. Finally, Franklin Resources Inc. grew its stake in Natera by 37.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after buying an additional 727,366 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.